These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2004-002176-42||Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecol...||bad-data|
|Listed as ongoing, but also has a completion date||2005-001300-39||A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of rep...||2008-06-19||bad-data|
|Not reported||2010-019424-31||A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type...||2013-04-30||due-trials|
|Not reported Terminated||2011-000756-42||A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.||2012-07-11||due-trials|
|Reported results||2011-006201-10||A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation||2016-12-09||due-trials|
|Exempt, with results||2012-002527-15||Study Brand Name : REPARO||2016-05-19||not-yet-due|
|Not reported||2013-002244-86||Effect of reparixin on long-term outcomes after pancreatic islet||2015-06-23||due-trials|
|Reported results||2013-004271-12||An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye||2015-01-30||due-trials|
|Ongoing||2014-003968-20||A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes||not-yet-due|
|Ongoing||2014-004796-23||A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer...||not-yet-due|
|Not reported||2016-002172-27||A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Nerve...||2017-09-04||due-trials|